Pain Drug Developers to Gather for 5th Annual Pain Therapeutics Summit in San Francisco Sept 20-21
For the past four years, this conference has provided attendees with thoughtful insight from key industry leaders and academic researchers.
This year’s event is bringing together speakers from numerous biopharmaceutical companies and academic institutions to present new research, including the following:
*New Approaches for Preclinical Assessment of Spontaneous Pain
*A Clinical Update on NGF Inhibition for the Treatment of Knee Osteoarthritis and other *Musculoskeletal Conditions
*Discovery of Differentiated TRPV1 Antagonists that Separate Efficacy from Hyperthermic Effects
*Pain Therapeutic Development in the Age of Translational Medicine
*An Examination of New and Upcoming Postsurgical Pain Therapies in Development
This year’s event will also feature a new panel discussion on the subject of new designs for clinical trials. Panelists will answer the question is it time to move beyond pain intensity as the primary endpoint in pain clinical trials?
Speakers at this conference will include:
*Frank Porreca, Ph.D., Professor of Pharmacology and Anesthesiology, University of Arizona
*Bernadette Hughes, Ph.D., Executive Director, Pain Therapeutic Area, Pfizer
*Christine Rauschkolb, MD, Ph.D., VP Pain Development, Johnson & Johnson
*Dr. Joseph Stauffer, Chief Medical Officer & VP, Corporate Strategy, PharmacoFore, Inc.
*Philip R. Kym, Ph.D., Associate Director II, Pain Discovery Research, Abbott Laboratories
*William K. Schmidt, Ph.D., Vice President, CrystalGenomics & CG Pharmaceuticals
and many others.
For the complete list of speakers as well as the agenda, please visit www.paintherapeuticsummit.com or call 1-312-244-3703.